Metilfenidato se salió del grupo . (@MIPserable) header
Metilfenidato se salió del grupo . (@MIPserable) profile picture

Homonormado 🏳️‍🌈 Muy hater.

Locus coeruleus
Joined September 2010
Photo by Metilfenidato se salió del grupo . (@MIPserable)
- ¿Padece alguna enfermedad crónica? -No. -¿Toma algún medicamento? -Metformina, Lord-satan.
18
693
119
3,872
Metilfenidato se salió del grupo . retweeted
번지수 잘못 찾은 닥터 둠🎄🧊
27
1,999
95
10,663
309,597
Te deseo lo mejor querido extraño
Dos extraños con recuerdos en común
1
2
155
Metilfenidato se salió del grupo . retweeted
1/Never a borring moment in #breastpath ... Core needle biopsy from a BI-RADS 3 lesion in elderly female. What is your diagnosis? Your vote is appreciated 👇👇👇 the only IHCs in the thread are CK5 and ER... E-cadherin expression was normal...
8
14
1
28
3,408
Metilfenidato se salió del grupo . retweeted
Porfa , 🙏🏼, súper a favor jaja
Cancelen las diapositivas medicas hechas con IA y traigan de vuelta el estilo clásico.
1
11
982
Metilfenidato se salió del grupo . retweeted
Micropapillary/cribriform ovarian serous borderline tumor may show confluent growth and appear almost solid Some pathologists previously called this “noninvasive low-grade serous carcinoma”—terminology not endorsed by the WHO True low-grade serous carcinoma requires stromal invasion. Extensive sampling is key to exclude it Dr. Turashvili. 2026 Annual Meeting of the International Society of Gynecological Pathologists #pathology #PathX #ISGyP #PathTwitter
11
39
1,307
Metilfenidato se salió del grupo . retweeted
Separating dedifferentiated endometrial carcinomas from carcinosarcomas MMRd: Favor DDEC p53 mutated: Favor carcinosarcoma SMARCA4/ARID1B/SMARCB1 loss: DDEC Dr. Lee. 2026 Annual Meeting of the International Society of Gynecological Pathologists #pathology #PathX #ISGyP
1
28
68
2,118
Metilfenidato se salió del grupo . retweeted
VER HASTA EL FINAL PARA ENTENDER EL PLANTEO. LO DOMÓ!! Video original: Young Bob X e IG: @YoungBobRB TikTok: @young_bob_pb – at Río Negro, Argentina
426
2,959
97
18,841
1,128,339
Metilfenidato se salió del grupo . retweeted
Core biopsy for mammographic calcifications. What is your diagnosis? CCH? FEA? ADH? DCIS? #breastpath
27
13
51
5,667
Metilfenidato se salió del grupo . retweeted
🚨 dMMR ≠ Lynch syndrome! A crucial distinction every oncologist should know. A new Lancet review highlights the diagnostic pathway: 🔬 MLH1/PMS2 loss? Check BRAF V600E and/or MLH1 methylation. 🧬 MSH2/MSH6 or isolated MSH6/PMS2 loss? Consider germline testing. 🔍 Germline negative? Look for double-somatic MMR alterations. 💡 Key message: Tumour MMR deficiency is a starting point, not a hereditary cancer diagnosis. 📊 Save this diagnostic algorithm! @oncoalert @esmo_open @myesmo @asco #LynchSyndrome #PrecisionOncology Full paper link in comment below ⬇️.
2
83
207
12,048
Confirmo. Siempre dicen “trabajas mucho “
Hoy mi jefa y maestra me dijo que no puedo salir con alguien que no sea médico , que porque es muy difícil que vayan a entender mi estilo de vida , así sean muy comprensivos 🥺
225
Metilfenidato se salió del grupo . retweeted
Separating dedifferentiated/undifferentiated endometrial carcinoma from high grade endometrioid adenocarcinoma Diffuse and strong keratin expression and/or diffuse PAX8 and/or ER expression argue against undifferentiated carcinoma Dr. Lee. 2026 Annual Meeting of the International Society of Gynecological Pathologists #pathology #PathX #ISGyP
15
46
1,460
Metilfenidato se salió del grupo . retweeted
IHC dedifferentiated/undifferentiated endometrial carcinomas -Loss of ARID1B, SMARCA4 or SMARCB1 -Complete loss or very focal expression of keratin, EMA, ER or PAX8 (in undifferentiated component) -MMR deficient in 2/3 of tumors -Wild Type p53 in 90-95% of tumors Dr. Lee. 2026 Annual Meeting of the International Society of Gynecological Pathologists #pathology #PathX #ISGyP
16
55
1,779
Metilfenidato se salió del grupo . retweeted
What is a Leydig cell? A Leydig cell is a steroidogenic cell that produces androgens (mainly testosterone). It has abundant eosinophilic-to-clear cytoplasm, round nuclei, and prominent nucleoli. Reinke crystals (rectangular, eosinophilic cytoplasmic inclusions) are pathognomonic but often absent Same cells, different names: • Follicle → theca interna • Hilum → hilus (hilar) cells • Benign stroma → stromal hyperthecosis • AGCT → luteinized adult granulosa cell tumor • SLCT → Sertoli-Leydig cell tumor Dr. Ordulu. Sex cord stromal tumors. 2026 Annual Meeting of the International Society of Gynecological Pathologists #GYNpath #PathTwitter #PathX #ISGyP #pathresidents
14
42
1,816
Metilfenidato se salió del grupo . retweeted
Uterine leiomyomas presenting during pregnancy and delivery can show necrosis In this setting, these findings are acceptable in a leiomyoma and should not lead to a diagnosis of STUMP Dr. Parra-Herran. High Impact Publications from recent GYN Path literature 2026 Annual Meeting of the International Society of Gynecological Pathologists #pathology #ISGyP #pathX
14
55
2,004
Metilfenidato se salió del grupo . retweeted
Sometimes angiolipomas can be extremely cellular and spindled. This was a breast lesion so it was especially alarming. The fibrin thrombi are your friends! Each tiny capillary has a cuff on "non-endothelial" cells, another friend.
1
24
89
3,083
Metilfenidato se salió del grupo . retweeted
DICER1-related Wilms-like uterine tumors and the broader “DICER1-related primitive polyphenotypic neoplasm” of the gyn tract/peritoneum are the same spectrum Key takeaway: polypoid/endometrial tumors with primitive glands (often subnuclear vacuoles), rhabdomyoblasts, fetal cartilage, periglandular condensation ± neuroectodermal elements → think DICER1 and test Link to papers: pubmed.ncbi.nlm.nih.gov/4099… pubmed.ncbi.nlm.nih.gov/4180… Dr. Parra-Herran. High Impact Publications from recent GYN Path literature 2026 Annual Meeting of the International Society of Gynecological Pathologists #pathology #ISGyP #pathX
30
69
2,417
Confianza, hija adoptiva de la necesidad y la esperanza.
122
Metilfenidato se salió del grupo . retweeted
CLEOPATRA did not test a fixed number of taxane cycles. We eventually landed on 6-8 cycles due to cumulative neuropathy. DB09 did not test a fixed number of T-DXd cycles. However, the lack of neuropathy with T-DXd provided the opportunity for more prolonged administration. The opportunity to keep the tumor under the pressure of cytotoxic treatment for longer. The effect of this can be seen in the DB09 PFS curves. They overlap for 4 months. They separate thereafter. 📉 Right after the taxane is stopped in the control arm, and maintenance is started, more patients start progressing. Progressions that are prevented in the T-DXd arm. And HER2+ disease progressions can be nasty. So, how many cycles of T-DXd should we give? There’s no magic number. We should let the disease features and patient preferences guide us. -Shorter duration for lower-risk disease. Longer duration if high-risk (recurrent, visceral, CNS, PI3K mut). -Shorter duration for disease that rapidly achieve complete response. Longer duration for disease that shrinks less. -Shorter duration for patients that experience bothersome side effects. Longer duration for patients that tolerate well. Determining the duration of T-DXd really takes the whole art of medicine. We’re out of the one-size fits all era in HER2+ breast cancer. nature.com/articles/s41571-0…
Are we stopping T-DXd + pertuzumab too soon? Drs. Paolo Tarantino (@PTarantinoMD) and Seth Wander make a point that may surprise many oncologists. With T-DXd + pertuzumab, the median time to maximum tumor reduction is about 11 to 12 months, and some patients take even longer. Many patients are labeled a partial response when they’re actually still on their way to something deeper. That challenges how many have practiced for years. Their message is that we shouldn’t be so quick to pull the combination after an arbitrary number of induction cycles. Full conversation here: communityhealth.media/tdxd-h… 💬 When do you switch to maintenance with T-DXd + pertuzumab?
4
43
4
139
16,962
Metilfenidato se salió del grupo . retweeted
👉 A 58-year-old male presented with a small intestinal mass and underwent surgical resection. What are your differentials?
4
6
1
20
1,642